Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTOPROL vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension,Off-label: heart failure (metoprolol component), edema
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.
250 mg orally twice daily
Bisoprolol: 10-12 hours, allowing once-daily dosing; Hydrochlorothiazide: 6-15 hours, prolonged in renal impairment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Metoprolol: primarily CYP2D6; Hydrochlorothiazide: not metabolized, excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 40-50% as unchanged drug and metabolites (hydrochlorothiazide and bisoprolol); Fecal/Biliary: <15%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Bisoprolol: 30% bound to albumin; Hydrochlorothiazide: 40-68% bound to plasma proteins (predominantly albumin).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Bisoprolol: 3.5 L/kg, reflecting extensive tissue distribution; Hydrochlorothiazide: 0.83 L/kg, indicating distribution in extracellular fluid.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: Bisoprolol 90% (high, first-pass negligible); Hydrochlorothiazide 65-75%.
70-90% (oral); 100% (IV).
Contraindicated if GFR <30 m L/min/1.73 m². For GFR 30-60 m L/min/1.73 m²: no dose adjustment required, but monitor potassium and creatinine. For GFR <30 m L/min/1.73 m²: do not use.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class A or B: no dose adjustment; use with caution. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for use in pediatric patients (safety and efficacy not established).
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lowest possible dose; monitor renal function and electrolytes. No specific dose adjustment required if renal function normal, but elderly more susceptible to hypotension and electrolyte imbalance.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Exacerbation of ischemic heart disease upon abrupt withdrawal of beta-blocker.,Bronchospasm in patients with bronchospastic disease.,May mask signs of hyperthyroidism or hypoglycemia.,Electrolyte disturbances (hypokalemia, hyponatremia) due to thiazide.,May increase serum uric acid and precipitate gout.,May cause photosensitivity reaction.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure.,Bronchial asthma or significant COPD.,Anuria or hypersensitivity to sulfonamide-derived drugs (thiazides).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
DUTOPROL should be taken 30 minutes after the same meal each day to reduce variability in absorption. Grapefruit juice inhibits CYP3A4 and can increase dutasteride levels; avoid concomitant consumption. High-fat meals may alter absorption, but consistent timing with a meal minimizes fluctuations. No other specific food interactions are known, but maintain a balanced diet and avoid excessive alcohol, which can worsen dizziness or hypotension.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Category D: First trimester exposure associated with fetal bradycardia, intrauterine growth restriction, and oligohydramnios; second and third trimester use may cause fetal hypotension, hypoglycemia, and decreased placental perfusion.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for bradycardia and hypotension.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Dose may need reduction due to increased plasma volume and clearance; individualize based on maternal blood pressure and fetal status.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
DUTOPROL is a fixed-dose combination of dutasteride (0.5 mg) and tamsulosin (0.4 mg) used for benign prostatic hyperplasia (BPH). Due to dutasteride's long half-life (~5 weeks), clinical effect on prostate volume may take 3–6 months. Tamsulosin, an alpha-1 blocker, can cause orthostatic hypotension, especially when initiated; titrate cautiously in elderly or those on antihypertensives. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) as they increase dutasteride exposure. Measure PSA before starting and periodically thereafter; dutasteride halves PSA levels after 6 months, so adjust interpretation. Do not use in women or children.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily, 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open the capsules; swallow them whole to avoid irritation.,This drug can cause dizziness, lightheadedness, or fainting, especially when first starting or if you take blood pressure medications. Get up slowly from sitting or lying down.,Avoid grapefruit juice and grapefruit products as they may affect how the drug works.,Inform your doctor if you experience any of the following: severe dizziness, difficulty urinating, chest pain, or signs of an allergic reaction (rash, itching, swelling).,Do not donate blood while taking this medication and for at least 6 months after stopping, as the drug can be present in blood and cause harm to a pregnant woman or her baby.,If you are having cataract surgery, tell your surgeon you are taking this drug, as it may increase the risk of intraoperative floppy iris syndrome (IFIS).,This medication may cause a decrease in sexual desire, difficulty with erections, or reduced semen volume. These side effects are generally reversible after stopping treatment.,Women who are pregnant or could become pregnant should avoid handling crushed or broken capsules due to risk of harm to the unborn baby.,Regular follow-ups with your healthcare provider for PSA testing and symptom monitoring are important to assess treatment response and adjust dose if needed.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTOPROL vs ALDOCLOR-250, answered by our medical review team.
DUTOPROL is a Antihypertensive Combination that works by Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTOPROL and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTOPROL is: 1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTOPROL and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTOPROL is classified as Category C. Category D: First trimester exposure associated with fetal bradycardia, intrauterine growth restriction, and oligohydramnios; second and third trimester use may cause fetal hypoten. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.